Ultragenyx Pharmaceutical RARE Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's accrued liabilities, current?
- Ultragenyx Pharmaceutical (RARE) reported accrued liabilities, current of $194M in Q1 2026.
- How has Ultragenyx Pharmaceutical's accrued liabilities, current changed year-over-year?
- Ultragenyx Pharmaceutical's accrued liabilities, current increased by 12.1% year-over-year, from $173.01M to $194M.
- What is the long-term trend for Ultragenyx Pharmaceutical's accrued liabilities, current?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's accrued liabilities, current has grown at a 19.6% compound annual growth rate (CAGR), from $108.49M to $265M.